Ischemic Stroke Epidemiology Forecast Report Coverage
The analyst's “Ischemic Stroke Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of ischemic stroke. It projects the future incidence and prevalence rates of ischemic stroke cases across various populations. The study covers age, gender, and type as major determinants of the ischemic stroke population. The report highlights patterns in the prevalence of ischemic stroke over time and projects future trends based on multiple variables.The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of ischemic stroke in the 8 major markets.
Regions Covered
- The United States
- Germany
- France
- Italy
- Spain
- The United Kingdom
- Japan
- India
Ischemic Stroke Understanding: Disease Overview
Ischemic stroke is a neurological condition caused by obstruction of blood flow to the brain, typically due to a thrombus or embolus blocking cerebral arteries. It accounts for nearly 85% of all stroke cases globally. Reduced oxygen supply leads to rapid neuronal damage and loss of brain function. Risk factors include hypertension, diabetes, obesity, smoking, and atrial fibrillation. The epidemiology of ischemic stroke highlights its growing global burden and impact on healthcare systems. Clinical manifestations include sudden weakness, speech impairment, and vision disturbances, requiring timely diagnosis.Ischemic Stroke Epidemiology Perspective
The ischemic stroke epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The analyst provides both current and predicted trends for the ischemic stroke epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for ischemic stroke and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.- According to the World Stroke Organization Global Stroke Fact Sheet 2025, based on GBD 2021 data, ischemic stroke constituted 65.3% of incident strokes globally, with the highest proportion recorded in high-income countries at 74.9%, compared to 63.4% in lower-middle-income countries.
- As per PMC-WSO Global Stroke Fact Sheet 2025 et al., in 2021, there were 93.8 million prevalent strokes globally, representing an 86% increase from 1990, with the bulk of global stroke burden, comprising 87% of deaths and 89% of disability-adjusted life years, residing in lower-income and lower-middle-income countries.
- According to CDC, high blood pressure, obesity, diabetes, high cholesterol, and smoking are the leading ischemic stroke risk factors. It is estimated that 1 in 3 adults in the United States has at least one of these risk factors, contributing significantly to population-level cerebrovascular disease burden.
- Studies confirm that disparities exist in stroke incidence and outcomes across racial and ethnic groups, with non-Hispanic Black and Pacific Islander adults consistently showing the highest stroke-related mortality rates in the United States, reflecting broader systemic inequities in cardiovascular risk management and healthcare access.
Country-wise Ischemic Stroke Epidemiology
The ischemic stroke epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.The United States and the United Kingdom represent well-documented high-income regions in ischemic stroke epidemiology, reflecting substantial disease burden and evolving trends. In the United States, approximately 795,000 stroke cases occur annually, with nearly 87% classified as ischemic, and around 7.8 million adults living with stroke history. In the United Kingdom, nearly 100,000 stroke cases are reported annually, with about 1.4 million survivors and incidence expected to rise. Collectively, these trends highlight a persistent and growing burden, emphasizing the need for continued advancements in prevention and management strategies.
Ischemic Stroke: Treatment Overview
Treatment of ischemic stroke focuses on rapid restoration of cerebral blood flow and prevention of further injury. Intravenous thrombolysis using tissue plasminogen activator (tPA) is the standard acute therapy within a defined time window. Mechanical thrombectomy is recommended for eligible patients with large vessel occlusion. Stroke treatment management also includes antiplatelet therapy and anticoagulants for secondary prevention. Long-term care emphasizes risk factor control, rehabilitation therapies, and lifestyle modifications to improve recovery and reduce recurrence risk.Key Questions Answered
- What are the key findings of ischemic stroke epidemiology in the 8 major markets?
- What will be the total number of patients with ischemic stroke across the 8 major markets during the forecast period?
- What was the country-wise ischemic stroke epidemiology scenario in the 8 major markets in the historical period?
- Which country will have the highest number of ischemic stroke patients during the forecast period of 2026-2035?
- Which key factors would influence the shift in the patient population of ischemic stroke during the forecast period of 2026-2035?
- What are the currently available treatments for ischemic stroke?
- What are the disease risks, signs, symptoms, and unmet needs of ischemic stroke?
Scope of the Ischemic Stroke Epidemiology Report
- The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of ischemic stroke based on several factors.
- Ischemic Stroke Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
- The ischemic stroke report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

